Clinical Trials Browser

Phase 1 × Completed × spartalizumab × Clear all

Esophageal Squamous Cell Carcinoma, Melanoma, Pancreatic Neoplasms, Triple Negative Breast Neoplasms

NCT03066648 2025-05-18

Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS

Bone Marrow Diseases, Hematologic Diseases, Leukemia, Leukemia, Myeloid, Myelodysplastic Syndromes, Preleukemia, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT04581343 2025-05-04

PanCAN-SR1

Phase 1 Completed

10 enrolled 26 charts

Gastrointestinal

Metastatic Pancreatic Ductal Adenocarcinoma

NCT04672434 2024-12-09

Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies

Phase 1 Completed

48 enrolled

GastrointestinalGynecologicHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Uterine Cervical Neoplasms, Esophageal Neoplasms, Mesothelioma, Neoplasm Metastasis, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT03523819 2024-09-19

A Study of CS1002 in Subjects with Advanced Solid Tumors

Phase 1 Completed

91 enrolled

Other solid neoplasm

Solid Tumor, Adult

NCT04641871 2024-06-26

Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies

Phase 1 Completed

78 enrolled

Gastrointestinal

Esophageal Squamous Cell Carcinoma, Neoplasm Metastasis, Cholangiocarcinoma

NCT03874897 2024-04-30

Chimeric Antigen Receptor T Cells Targeting claudin18.2 in Solid Tumors.

Phase 1 Completed

134 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT02828098 2024-01-29

Exploratory Study of BO-112 in Adult Patients With Aggressive Solid Tumors

Phase 1 Completed

44 enrolled

Tumor-Agnostic

Neoplasms

NCT02658981 2023-10-06

Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18)

Phase 1 Completed

63 enrolled

CNSSarcoma

Brain Neoplasms, Glioblastoma, Gliosarcoma

NCT01176474 2023-07-19

Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma

Phase 1 Completed

73 enrolled

Dermatologic

Melanoma

NCT03311412 2023-05-30

Sym021 Monotherapy, in Combination With Sym022 or Sym023, and in Combination With Both Sym022 and Sym023 in Patients With Advanced Solid Tumor Malignancies or Lymphomas

Phase 1 Completed

89 enrolled

Lymphoid

Lymphoma, Neoplasm Metastasis

NCT01176461 2023-01-18

Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558

Phase 1 Completed

127 enrolled

Dermatologic

Melanoma

NCT02890069 2023-01-11

A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat

Phase 1 Completed

298 enrolled

BreastGastrointestinalGenitourinaryThoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT02900664 2022-03-29

A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)

Phase 1 Completed

283 enrolled

BreastGastrointestinalThoracic

Adenocarcinoma of Lung, Adenocarcinoma, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Intestinal Neoplasms, Lung Neoplasms, Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Carcinoma, Ductal, Triple Negative Breast Neoplasms

NCT03111992 2022-02-09

Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma

Phase 1 Completed

26 enrolled

Plasma cell

Hematologic Diseases, Multiple Myeloma, Neoplasms, Plasma Cell

NCT02947165 2022-01-31

Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.

Phase 1 Completed

120 enrolled

BreastGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Kidney Neoplasms, Liver Neoplasms, Lung Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT02403193 2022-01-12

AdenONCO

Phase 1 Completed

92 enrolled

Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT02112032 2021-05-05

Treatment of Advanced Melanoma With MK-3475 and Peginterferon

Phase 1 Completed

43 enrolled

Dermatologic

Melanoma

NCT02740270 2021-02-21

Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and Lymphomas

Phase 1 Completed

92 enrolled

Lymphoid

Lymphoma

NCT02988440 2020-12-19

Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular Patients

Phase 1 Completed

20 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT03081494 2020-12-11

Phase Ib Study of PDR001 in Combination With Regorafenib in Adult Patients With Previously Treated Metastatic Colorectal Cancer

Phase 1 Completed

10 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT02678260 2018-06-08

Phase I Study of PDR001 in Patients With Advanced Malignancies.

Phase 1 Completed

18 enrolled

Advanced Malignancies

Clinical Trials

A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands

Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS

PanCAN-SR1

Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies

A Study of CS1002 in Subjects with Advanced Solid Tumors

Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies

Chimeric Antigen Receptor T Cells Targeting claudin18.2 in Solid Tumors.

Exploratory Study of BO-112 in Adult Patients With Aggressive Solid Tumors

Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18)

Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma

Sym021 Monotherapy, in Combination With Sym022 or Sym023, and in Combination With Both Sym022 and Sym023 in Patients With Advanced Solid Tumor Malignancies or Lymphomas

Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558

A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat

A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)

Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma

Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.

AdenONCO

Treatment of Advanced Melanoma With MK-3475 and Peginterferon

Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and Lymphomas

Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular Patients

Phase Ib Study of PDR001 in Combination With Regorafenib in Adult Patients With Previously Treated Metastatic Colorectal Cancer

Phase I Study of PDR001 in Patients With Advanced Malignancies.